Peripheral T-Cell Lymphoma Market Insights-01

DelveInsight’s Peripheral T-Cell Lymphoma Report delivers an in-depth understanding of the Peripheral T-Cell Lymphoma, historical and forecasted epidemiology, and the Peripheral T-Cell Lymphoma market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some Key Highlights from the Peripheral T-Cell Lymphoma Market Report

  • In 2020, the total incident population of Peripheral T-Cell Lymphoma (PTCL) in the seven global markets was 17,057, with this number projected to increase over the forecast period.
  • PTCL is divided into four stages based on the affected area: Stage I, Stage II, Stage II, Stage III, and Stage IV. Stage I, stage II, stage III, and stage IV. PTCL incident cases in the United States were 929, 771, 1,522, and 3,261, respectively, in 2020.
  • Emerging therapy in the PTCL market include Copictra (Duvelisib) (Secura Bio), Tislelizumab (BeiGene), Keytruda (Merck Sharp & Dohme Corp), SP-02 (Darinaparsin, ZIO-101) (Solasia Pharma), HBI-8000 (HUYA Bioscience International/Quintiles), Azacitidine (CC-486) (Celgene Corporation), Tipifarnib (Kura Oncology), AFM13 (Affimed GmbH), Masitinib (AB Science), other.
  • Major companies in the PTCL market are Secura Bio, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, HUYA Bioscience International/Quintiles, Celgene Corporation, Kura Oncology, Affimed GmbH, AB Science, among others.
  • The rise in Peripheral T-Cell Lymphoma Market Size is due to an increase in the incidence population of Peripheral T-Cell Lymphoma (PTCL) in the 7MM population.

Request sample page @ Peripheral T-Cell Lymphoma Market Insights

The Peripheral T-Cell Lymphoma market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Peripheral T-Cell Lymphoma market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.

Peripheral T-Cell Lymphoma: Disease Overview

Peripheral T-cell lymphoma (PTCL) is a category of aggressive lymphomas that arise from mature T-cells and natural killer (NK) cells. It accounts for 10–15 percent of all non-Hodgkin lymphomas across the world.

Nonsurgical and surgical procedures are currently available, with the nonsurgical protocol including physical therapy and medications. Surgical protocols, on the other hand, include procedures like discectomy or microdiscectomy, laminectomy or laminotomy.

Peripheral T-Cell Lymphoma Epidemiology Segmentation

  • Peripheral T-Cell Lymphoma Total Incident Cases
  • Peripheral T-Cell Lymphoma Stage-Specific Incident Cases
  • Peripheral T-Cell Lymphoma Subtype- Specific Incident Cases

Learn more about epidemiology @ Peripheral T-Cell Lymphoma Epidemiology

Peripheral T-Cell Lymphoma Treatment Landscape

Currently, there are supportive care options available for Peripheral T-Cell Lymphoma (PTCL), such as conservative (nonsurgical) and surgical approaches. Physical exercise, Behavioural approaches, and pharmacological therapies are also included in the conservative management of Peripheral T-Cell Lymphoma (PTCL).

Only five FDA-approved products for PTCL treatments are available:

  • Beleodaq (Belinostat): Acrotech Biopharma
  • Istodax (Romidepsin): Celgene
  • Folotyn (Pralatrexate): Acrotech Biopharma
  • Arranon (Nelarabine): GlaxoSmithKline
  • Adcetris (Brentuximab vedotin): Seattle Genetics

Peripheral T-Cell Lymphoma Market

The market size of PTCL in  the seven major markets was found to be USD 948 Million in 2020.

In the forecasted period (2021–2030), the rapid shift in the market is primarily due to the launch of Adcetris, as well as the extensive clinical pipeline and the upcoming launch of emerging therapies such as Azacitidine (CC-486), COPIKTRA (Duvelisib), and others.

Peripheral T-Cell Lymphoma Pipeline Therapies and Key Companies

  • Copictra (Duvelisib): Secura Bio
  • Tislelizumab: BeiGene
  • Keytruda: Merck Sharp & Dohme Corp
  • SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
  • HBI-8000: HUYA Bioscience International/Quintiles
  • Azacitidine (CC-486): Celgene Corporation
  • Tipifarnib: Kura Oncology
  • AFM13: Affimed GmbH
  • Masitinib: AB Science

Gain more knowledge about emerging drugs @ Peripheral T-Cell Lymphoma Emerging Drugs and Companies

Peripheral T-Cell Lymphoma Market Drivers

  • Use of Combination Therapies
  • Upcoming novel therapies in pipeline for the treatment of PTC
  • An upsurge in Research and Development

Peripheral T-Cell Market Barriers

  • Low rates of incidence
  • Less expertise in diagnosis and rarity of PTCL subtypes
  • Lack of awareness

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

PTCL Key Companies: Secura Bio, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, HUYA Bioscience International/Quintiles, Celgene Corporation, Kura Oncology, Affimed GmbH, AB Science, among others.

PTCL Pipeline Therapies: Copictra (Duvelisib) (Secura Bio), Tislelizumab (BeiGene), Keytruda (Merck Sharp & Dohme Corp), SP-02 (Darinaparsin, ZIO-101) (Solasia Pharma), HBI-8000 (HUYA Bioscience International/Quintiles), Azacitidine (CC-486) (Celgene Corporation), Tipifarnib (Kura Oncology), AFM13 (Affimed GmbH), Masitinib (AB Science), other.

PTCL Market Segmentation: By Geography, By PTCL Therapies

Analysis: Comparative and conjoint analysis of PTCL emerging therapies

SWOT

Cases Studies

KOL’s Views

Analyst’s Views

For more information visit Peripheral T-Cell Lymphoma Market Insight Report

Table of Contents

1. Key Insights
2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)
3. Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance
4. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)
5. PTCL: Case Reports
6. PTCL: Epidemiology and Patient Population
7. United States Epidemiology
8. EU5 Epidemiology
9. Japan Epidemiology
10. PTCL: Treatment
11. PTCL: Unmet needs
12. PTCL: Marketed Drugs
13. PTCL: Emerging Drugs
14. Peripheral T-cell Lymphoma (PTCL): Seven Major Market Analysis
15. CD30 expression in peripheral T-cell lymphomas
16. Expected Launch Year of Emerging Therapies of PTCL
17. Attribute Analysis Phase III
18. Attribute Analysis Phase II
19. United States Market Outlook
20. EU-5 Market Outlook
21. Japan Market Outlook
22. PTCL: Market Drivers
23. PTCL: Market Barriers
24. SWOT Analysis
25. Reimbursement and Market Access
26. Recognized Establishments
27. Appendix
28. DelveInsight Capabilities
29. Disclaimer
30. About DelveInsight

Know more about report offerings @ Peripheral T-Cell Lymphoma Market

Related Reports   

Diabetic Peripheral Neuropathy Market 

Get comprehensive historical and forecast analysis of Diabetic Peripheral Neuropathy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Helixmith, Novaremed Ltd., Grünenthal GmbH, Aptinyx, among others.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market

DelveInsight’s “Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD), historical and forecasted epidemiology as well as the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Peripheral Nerve Injuries Market

Get comprehensive historical and forecast analysis of Peripheral Nerve Injuries Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Toyobo, Polyganics, Axogen Corporation, Neuraptive Therapeutics, among others.

Peripheral Neuropathic Pain Market

DelveInsight’s “Peripheral Neuropathic Pain – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Neuropathic Pain, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Peripheral SpA Market

DelveInsight’s “Peripheral SpA – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral SpA, historical and forecasted epidemiology as well as the Peripheral SpA market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Peripheral Vascular Interventions Market

DelveInsight’s “Peripheral Vascular Interventions – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Peripheral Vascular Interventions , historical and forecasted epidemiology as well as the Peripheral Vascular Interventions market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chemotherapy-Induced Peripheral Neuropathy Market

DelveInsight’s ‘Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

Chronic Periodontitis Market

DelveInsight’s “Chronic Periodontitis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Periodontitis, historical and forecasted epidemiology as well as the Chronic Periodontitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Adult T-Cell Leukemia-Lymphoma Market

DelveInsight’s “Adult T-Cell Leukemia-Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Adult T-Cell Leukemia-Lymphoma , historical and forecasted epidemiology as well as the Adult T-Cell Leukemia-Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Natural Killer T Cell Lymphoma Market

DelveInsight’s “Natural Killer T Cell Lymphoma (NKTL) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Natural Killer T Cell Lymphoma (NKTL), historical and forecasted epidemiology as well as the Natural Killer T Cell Lymphoma (NKTL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get in touch with our Business executive @ Lymphoma Disease Market Insights to know more

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Tags: , , , ,

See Campaign: https://www.delveinsight.com/
Contact Information:

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Tags:
IPS, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English

image

Contact Information:

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter